Europe Radiotherapy Market Outlook, 2031
The Europe Radiotherapy Market is segmented into By Therapy Type (External Beam Radiotherapy, Internal / Brachytherapy, Systemic Radiotherapy); By Offering (Radiotherapy Systems/Equipment, Software & Services); By Technology (Image-Guided Radiotherapy, Intensity-Modulated Radiotherapy, Stereotactic Radiosurgery, Proton Beam Therapy, 3D-Conformal Radiotherapy, Volumetric Modulated Arc Therapy, Other Technology); By Application (Breast Cancer, Prostate Cancer, Lung Cancer, Head & Neck Cancer, Central Nervous System / Brain, Gastro-intestinal, Other Applications); By End User (Hospitals & Integrated Cancer Centers, Standalone Radiotherapy Centers, Academic/Research Institutions, Other Healthcare Facilities).
- Bonafide Research
- 24-08-2026
- Pages : 120
- Figures : 9
- Tables : 34
- Region : Europe
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Europe Radiotherapy Market is anticipated to add to more than 1.3 Billion by 2026-31.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Largest MarketGermany
- Fastest Market Spain
- Market Difference(2026-31) USD 1.32 Billion
- Format
Featured Companies
- 1. Siemens Healthineers
- 2. Canon Medical Systems Corporation
- 3. Accuray Incorporated
- 4. Brainlab
- 5. Carl Zeiss AG,
- 6. Epic Systems Corporation
- More...
Radiotherapy Market Analysis
The Europe radiotherapy market is a mature yet dynamic regional market, underpinned by a high cancer burden, substantial public healthcare expenditure, and a strong emphasis on equitable access to care across its diverse nations. The European Society for Radiotherapy and Oncology (ESTRO) has called for a repositioning of radiation oncology as a core discipline in cancer care, scientifically, clinically, and politically. The European Union has allocated USD 5.3 Billion to health programs under Horizon Europe for 2021 2027, demonstrating a significant financial commitment to healthcare innovation. The market is characterised by the widespread adoption of advanced modalities including Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), and Stereotactic Body Radiotherapy (SBRT). However, the region is also marked by significant disparities in equipment density and age, with the COCIR noting that most European countries do not meet its target goal of 7 radiation therapy systems (linacs) per million population. According to the research report, "Europe Radiotherapy Market Outlook, 2031," published by Bonafide Research, the Europe Radiotherapy Market is anticipated to add to more than 1.3 Billion by 2026-31. Western European nations such as Germany, France, and the United Kingdom are the primary contributors to regional spending, supported by their advanced healthcare systems and large installed bases. Southern and Eastern European countries, including Italy, Spain, and Poland, represent significant growth opportunities due to ongoing infrastructure modernisation programs and rising cancer incidence. External Beam Radiotherapy (EBRT) represents the largest therapy segment across Europe, driven by the extensive installed base of linear accelerators. Systemic radiotherapy is the fastest growing therapy segment, fueled by the emergence of novel radiopharmaceuticals. Radiotherapy systems and equipment hold the largest offering segment share, while software and services represent the fastest growing segment, reflecting the increasing digitalisation of radiation oncology. Breast cancer is the largest application segment, while central nervous system and brain cancers are the fastest growing. Hospitals and integrated cancer centres dominate end use spending, with academic and research institutions growing fastest.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• High cancer burden and increasing demand for radiotherapy: The primary driver of the European radiotherapy market is the substantial and growing cancer burden across the region. The ESTRO HERO (Health Economics in Radiation Oncology) project has estimated that about 4 million new cancer patients are predicted in 2025 in Europe, a 15.9% increase compared to the number in 2012, and about 2 million cancer patients would have an indication for radiotherapy in 2025, a 16.1% increase from 2012. This increasing demand is driven by an ageing population, improved cancer detection, and the expansion of clinical indications for radiotherapy. The ESTRO manifesto emphasises the need to reposition radiation oncology as a core discipline in integrated oncology care, further supporting market growth.• Sustained government investment and infrastructure modernisation: European governments are making substantial investments in modernising radiotherapy infrastructure. The UK's NHS Supply Chain has procured 28 new 'cutting edge' linear accelerator (LINAC) radiotherapy systems in 2025/26, backed by centralised government funding provided by NHS England for NHS hospitals in need of replacement systems, delivering savings of £21.8 million for the NHS. In Italy, the National Recovery and Resilience Plan (PNRR) has funded a Consip framework agreement for 62 linear accelerators and systems for radiotherapy, valued at approximately €130 million. Germany and France are also investing significantly in upgrading obsolete infrastructure. This sustained investment ensures consistent demand for equipment, installation services, and comprehensive maintenance contracts.
• Strong focus on research and innovation: Europe is a global leader in radiotherapy research and innovation. The Horizon Europe programme has allocated substantial funding for health research, including projects on advanced radiotherapy technologies such as FLASH and microbeam therapy, and isotope production. ESTRO's Health Economics in Radiation Oncology (HERO) project has developed a knowledge base and model for costing and health economic evaluation of radiation treatments for European countries. This strong research focus drives the adoption of cutting edge technologies and creates demand for advanced treatment planning systems and specialised services.
Market Challenges
• Significant disparities in equipment density and age across Europe: A major challenge facing the European radiotherapy market is the broad disparity in equipment density and age between countries. The COCIR has identified an "alarmingly high percentage" of medical imaging equipment in Europe that is more than 10 years old. COCIR adopted a target goal of 7 radiation therapy systems (linacs) per million population, based on both GLOBOCAN and IAEA published recommendations; however, most European countries still do not meet this objective. This disparity leads to unequal access to advanced radiotherapy treatments, with many centres struggling with outdated equipment and longer waiting times.• Workforce shortages in radiation oncology: Staffing shortages remain a key concern across Europe, with many centres facing difficulties in attracting and retaining qualified medical physicists, dosimetrists, and radiation therapists. This shortage has reinforced the demand for workflow automation, distributed radiotherapy networks, and faster AI supported treatment planning protocols. The workforce constraints limit the capacity to operate newly acquired equipment and can lead to delays in treatment, impacting patient outcomes and overall market efficiency.
• Budget constraints and uneven access to cutting edge equipment: While Western European countries continue to invest in radiotherapy infrastructure, Eastern and Southern European nations face significant budget constraints. This leads to uneven access to cutting edge radiotherapy equipment compared to Western European markets. Treatments in Europe are estimated to be 10 30% below optimal levels due to insufficient equipment and lack of availability of the latest radiotherapy treatment technologies, creating a substantial need for investment and highlighting the infrastructure gaps across the region.
Market Trends
• Shift toward value based radiotherapy and personalised medicine: A major trend shaping the European radiotherapy market is the increasing focus on value based radiation oncology and personalised medicine. The ESTRO HERO project has introduced national level cost accounting tools using time driven activity based costing to support resource planning and reimbursement. This shift is driving demand for advanced treatment planning systems, AI powered tools for adaptive radiotherapy, and integrated solutions that enable more personalised and efficient treatment delivery.• Digital transformation and AI integration in radiotherapy: The adoption of artificial intelligence and digital technologies is accelerating across European radiotherapy centres. The workforce shortage has reinforced the demand for workflow automation and faster AI supported treatment planning protocols. Healthcare providers are investing in enterprise asset management platforms, predictive maintenance capabilities, and AI powered treatment planning systems to improve efficiency and patient outcomes. Germany and France are seeing a continued transition from other systems to advanced platforms like RayStation, with major networks replacing Pinnacle and Eclipse.
• Expansion of proton therapy and advanced particle therapy centres: Europe continues to expand its proton therapy infrastructure, with increasing investment in advanced particle therapy centres across the region. Spain has approved a framework agreement for proton therapy referrals with a base budget of €2.1 million, with 2025 seen as a key year for advancing deployment of the proton therapy network. This trend reflects the growing clinical evidence supporting proton therapy for specific indications and is driving significant capital investment and creating new demand for specialised maintenance and service contracts.
Radiotherapy Segmentation
| By Therapy Type | External Beam Radiotherapy (EBRT) | |
| Internal / Brachytherapy | ||
| Systemic Radiotherapy | ||
| By Offering | Radiotherapy Systems/Equipment | |
| Software & Services | ||
| By Technology | Image-Guided Radiotherapy | |
| Intensity-Modulated Radiotherapy | ||
| Stereotactic Radiosurgery | ||
| Proton Beam Therapy | ||
| 3D-Conformal Radiotherapy | ||
| Volumetric Modulated Arc Therapy | ||
| Other Technology | ||
| By Application | Breast Cancer | |
| Prostate Cancer | ||
| Lung Cancer | ||
| Head & Neck Cancer | ||
| Central Nervous System / Brain | ||
| Gastro-intestinal | ||
| Other Applications | ||
| By End User | Hospitals & Integrated Cancer Centers | |
| Standalone Radiotherapy Centers | ||
| Academic/Research Institutions | ||
| Other Healthcare Facilities | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
External Beam Radiotherapy (EBRT) is the largest therapy segment because the extensive installed base of linear accelerators and the clinical dominance of advanced techniques including IMRT, IGRT, VMAT, and SBRT make it the modality of choice for a broad spectrum of malignancies across Europe. External Beam Radiotherapy (EBRT) represents the largest therapy segment in the Europe radiotherapy market, driven by the extensive installed base of linear accelerators and the clinical dominance of advanced techniques. EBRT is the modality of choice for a broad spectrum of malignancies due to its effectiveness, non invasiveness, and well established evidence base. The segment continues to benefit from technological enhancements, including MR guided linear accelerators and advanced stereotactic delivery systems. The presence of a large number of EBRT centres across hospital systems, academic institutions, and freestanding facilities across Western, Southern, and Northern Europe contributes to its sustained leadership position. Major equipment suppliers including Varian Medical Systems, Siemens Healthineers, and Elekta dominate the EBRT segment with their advanced LINAC platforms. The UK's NHS Supply Chain procured 28 new LINAC systems in 2025/26, while Italy's PNRR has funded 62 linear accelerators, demonstrating sustained investment in this segment. Systemic Radiotherapy is the fastest growing therapy segment because the emergence of novel radiopharmaceuticals and targeted radionuclide therapies is creating new treatment options for specific malignancies, supported by substantial research funding and regulatory frameworks. Systemic Radiotherapy represents the fastest growing therapy segment in the Europe radiotherapy market, fueled by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies for treating metastatic prostate cancer, neuroendocrine tumors, and certain lymphomas. The European Union's regulatory framework for Peptide Receptor Radionuclide Therapy (PRRT) is multi layered, encompassing pharmaceutical, nuclear safety, and radiation protection regulations. The PRRT market in the European Union is forecast to grow substantially through 2035. Horizon Europe funding for Euratom research includes projects to improve the safe use and reliable supply of medical radionuclides. This segment is a focal point for innovation and represents a significant area for future market expansion across Europe. Radiotherapy Systems/Equipment is the largest offering segment because high capital costs, continuous technological innovation, and the replacement of aging equipment drive substantial investment in treatment delivery systems across European healthcare systems. Radiotherapy Systems/Equipment represents the largest offering segment in the Europe radiotherapy market, driven by the high capital cost of advanced treatment delivery systems. This includes linear accelerators, proton therapy systems, gamma knives, robotic radiosurgery platforms, and brachytherapy afterloaders. Growth in this segment is sustained by continuous technological innovation, the replacement of aging equipment across the installed base, and the expansion of new cancer centres and proton therapy facilities. Europe continues to invest massively in upgrading obsolete infrastructure, with over 3,000 LINACs installed across the continent. Major suppliers include Varian Medical Systems, Siemens Healthineers, Elekta, Accuray, and IBA. Software & Services is the fastest growing offering segment because the increasing digitalisation of radiation oncology, workforce shortages, and the need for comprehensive lifecycle management are driving demand for advanced software solutions and maintenance services. Software & Services represents the fastest growing offering segment in the Europe radiotherapy market, reflecting the increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems, AI powered contouring and dose optimisation tools, image registration and fusion platforms, and patient data management systems. The services component encompasses installation, comprehensive maintenance, clinical training, physics support, cybersecurity updates, and remote technical support. The trend toward outsourcing maintenance and support services, driven by workforce constraints and the growing complexity of equipment, is a key driver for this segment. Healthcare providers seek to manage operational costs while ensuring high uptime and compliance, creating sustained demand for comprehensive service agreements. Germany and France are seeing a continued transition to advanced treatment planning systems like RayStation. Proton Beam Therapy is the fastest growing technology segment because the expansion of proton therapy infrastructure across Europe, supported by government investment and clinical evidence, is driving significant investment in this advanced modality. Proton Beam Therapy represents the fastest growing technology segment in the Europe radiotherapy market, reflecting the expansion of proton therapy infrastructure across the region. Proton therapy offers significant advantages for paediatric cancers, brain tumours, and head and neck cancers by reducing dose to surrounding healthy tissues. The proton accelerator segment dominates the market as it represents the most complex and expensive component in proton therapy systems. Spain has approved a framework agreement for proton therapy referrals with a base budget of €2.1 million, with 2025 seen as a key year for advancing deployment of the proton therapy network. The rotating proton therapy systems segment achieved the largest market share due to superior flexibility in beam guidance. Major suppliers include IBA and Varian Medical Systems. Breast Cancer is the largest application segment because high incidence rates and the well established role of radiotherapy in both breast conserving therapy and post mastectomy settings sustain steady demand for treatment equipment and planning software across Europe. Breast Cancer represents the largest application segment in the Europe radiotherapy market, driven by the high incidence of breast cancer and the well established role of radiotherapy in treatment. Breast cancer is the most frequently diagnosed cancer among women across Europe, sustaining steady demand for treatment equipment and planning software. Techniques including accelerated partial breast irradiation, hypofractionated whole breast irradiation, and deep inspiration breath hold are standard practice across the region. The expansion of screening programmes has led to earlier detection, further driving demand for radiotherapy as a component of multidisciplinary care. Central Nervous System / Brain is the fastest growing application because the use of stereotactic radiosurgery for brain metastases, the development of sophisticated MR guided radiotherapy for high grade gliomas, and updated clinical guidelines, including ESTRO/EANO 2025 recommendations for reirradiation and delineation, are driving significant investment in advanced equipment and software. Central Nervous System / Brain represents the fastest growing application in the Europe radiotherapy market, driven by the use of stereotactic radiosurgery for brain metastases, the development of sophisticated MR guided radiotherapy for high grade gliomas, and the publication of updated clinical guidelines. ESTRO/EANO 2025 recommendations for reirradiation of glioblastoma and delineation of radiotherapy in diffuse gliomas G2 and G3 have clarified and expanded the role of radiation for certain CNS malignancies. The technological complexity and precision requirements of CNS radiotherapy drive significant investment in advanced equipment and software. Dedicated systems including Gamma Knife and Cyberknife are available across major European centres, with growth supported by expanding clinical indications and the availability of advanced imaging for treatment planning. Hospitals & Integrated Cancer Centres are the largest end user segment because these institutions provide comprehensive, multidisciplinary cancer care and possess the infrastructure, capital resources, and clinical expertise to invest in the full range of advanced radiotherapy technologies across Europe. Hospitals & Integrated Cancer Centres represent the largest end user segment in the Europe radiotherapy market, as these institutions provide comprehensive, multidisciplinary cancer care and possess the infrastructure, capital resources, and clinical expertise to invest in the full range of advanced radiotherapy technologies. These organisations often serve as regional referral centres, manage complex and high acuity cases, and operate the most diverse equipment fleets including multiple LINACs, proton systems, and brachytherapy programmes. The hospitals segment reflects the concentration of advanced radiotherapy services in hospital settings across European healthcare systems. Academic/Research Institutions are the fastest growing end user segment because their central role in advancing the field through clinical trials, technology validation, and workforce training drives high adoption rates of innovative technologies across Europe. Academic/Research Institutions represent the fastest growing end user segment in the Europe radiotherapy market, reflecting their central role in advancing the field. They conduct Horizon Europe funded and industry sponsored clinical trials, develop and test new technologies including FLASH radiotherapy and novel radiopharmaceuticals, validate emerging treatment protocols, and train the next generation of radiation oncologists, medical physicists, and therapists. ESTRO's initiatives, including education, research networks, and oncopolicy engagement, underscore the discipline's broad scope and societal value. Their high adoption rate of innovative technologies makes them a key driver of market growth and a bellwether for broader clinical adoption.
to Download this information in a PDF
Radiotherapy Market Regional Insights
Germany dominates the European radiotherapy market because of its advanced healthcare infrastructure, high healthcare expenditure, strong presence of global medical device manufacturers, and a well established network of academic medical centres and community hospitals. Germany represents the largest radiotherapy market in Europe, supported by its position as the region's economic powerhouse and a leader in healthcare innovation. Germany is home to a large installed base of linear accelerators and a well established network of academic medical centres and community hospitals. The country continues to invest in upgrading obsolete infrastructure, with major networks transitioning to advanced treatment planning systems. The Germany Radiotherapy Market was estimated at USD 206 Million in 2025. The country's strong presence of global medical device manufacturers, including Siemens Healthineers, and a favourable reimbursement environment further support market growth. Germany is expected to remain the dominant national market and a key driver of the European radiotherapy market. The United Kingdom provides significant growth opportunities because the NHS is making substantial investments in modernising radiotherapy infrastructure, with NHS Supply Chain procuring 28 new LINAC systems in 2025/26. The United Kingdom represents a mature but rapidly modernising radiotherapy market, supported by the National Health Service's commitment to improving cancer care. NHS Supply Chain has procured 28 'cutting edge' new linear accelerator (LINAC) radiotherapy systems in 2025/26, delivering savings of £21.8 million for the NHS. The modern technology reduces delays to treatment and, in some cases, reduces the number of hospital visits a patient needs by half, helping to cut waiting lists faster. However, the UK faces challenges: the NHS LINAC network is ageing and relatively scant, with the UK lagging behind comparable European countries. England has only 4.8 LINACs per million inhabitants, well below the COCIR target of 7 per million. The upcoming National Cancer Plan presents an opportunity for long term renewal and investment in radiotherapy equipment. The NHS expects up to an additional 12,750 radiotherapy sessions a year by 2027 as a result of the LINAC programme. Italy represents an emerging market opportunity because the National Recovery and Resilience Plan (PNRR) is funding a major modernisation of radiotherapy infrastructure, with Consip procuring 62 linear accelerators valued at approximately €130 million. Italy represents a significant growth opportunity in the European radiotherapy market, driven by substantial government investment through the National Recovery and Resilience Plan (PNRR). Consip has published tenders for 62 linear accelerators and systems for radiotherapy (respiratory gating, patient positioning control, in vivo dosimetry), valued at approximately €130 million. These initiatives are part of the broader PNRR investment in Mission 6 (Health), Component 2 "Innovation, research and digitalisation of the NHS". The framework agreement, developed in collaboration with scientific societies AIRO and AIFM, guarantees the widest choice for public administrations. Individual PNRR funded LINAC purchases are being made across Italian regions, with investments ranging from €2.19 million to €2.5 million per unit. This sustained investment cycle ensures consistent demand for equipment, installation services, training, and comprehensive maintenance contracts. France continues to invest in radiotherapy infrastructure through centralised procurement, with the GCS UniHA framework for radiotherapy equipment and software supporting modernisation across public hospitals. France represents a mature radiotherapy market with a well established public healthcare system. The GCS UniHA framework for radiotherapy equipment and software supports procurement across French public hospitals. The France Radiotherapy Market was estimated at USD 145 Million in 2025. Major networks are transitioning from existing systems to advanced treatment planning platforms. The country continues to invest in upgrading its radiotherapy infrastructure, supported by strong government commitment to cancer care and innovation. Spain represents an emerging market opportunity because 2025 has been identified as a key year for advancing the deployment of the proton therapy network, with a framework agreement for proton therapy referrals approved. Spain represents a significant growth opportunity in the European radiotherapy market, particularly in the proton therapy segment. 2025 has been identified as a key year for advancing the deployment of the proton therapy network across autonomous communities. The Spanish government has approved a framework agreement for proton therapy referrals with a base budget of €2.1 million. The country is also investing in modern LINAC infrastructure, supported by regional health authorities.
to Download this information in a PDF
Companies Mentioned
- Siemens Healthineers
- Canon Medical Systems Corporation
- Accuray Incorporated
- Brainlab
- Carl Zeiss AG,
- Epic Systems Corporation
- Becton, Dickinson and Company
- Elekta AB (publ)
- RaySearch Laboratories AB
- PTW-Freiburg GmbH
- C-RAD AB
- BEBIG Medical GmbH
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Europe Radiotherapy Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Therapy Type
- 6.4. Market Size and Forecast, By Offering
- 6.5. Market Size and Forecast, By Technology
- 6.6. Market Size and Forecast, By Application
- 6.7. Market Size and Forecast, By End User
- 6.8. Germany Radiotherapy Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Therapy Type
- 6.8.3. Market Size and Forecast By Offering
- 6.8.4. Market Size and Forecast By Application
- 6.8.5. Market Size and Forecast By End User
- 6.9. United Kingdom (UK) Radiotherapy Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Therapy Type
- 6.9.3. Market Size and Forecast By Offering
- 6.9.4. Market Size and Forecast By Application
- 6.9.5. Market Size and Forecast By End User
- 6.10. France Radiotherapy Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By Therapy Type
- 6.10.3. Market Size and Forecast By Offering
- 6.10.4. Market Size and Forecast By Application
- 6.10.5. Market Size and Forecast By End User
- 6.11. Italy Radiotherapy Market Outlook
- 6.11.1. Market Size by Value
- 6.11.2. Market Size and Forecast By Therapy Type
- 6.11.3. Market Size and Forecast By Offering
- 6.11.4. Market Size and Forecast By Application
- 6.11.5. Market Size and Forecast By End User
- 6.12. Spain Radiotherapy Market Outlook
- 6.12.1. Market Size by Value
- 6.12.2. Market Size and Forecast By Therapy Type
- 6.12.3. Market Size and Forecast By Offering
- 6.12.4. Market Size and Forecast By Application
- 6.12.5. Market Size and Forecast By End User
- 6.13. Russia Radiotherapy Market Outlook
- 6.13.1. Market Size by Value
- 6.13.2. Market Size and Forecast By Therapy Type
- 6.13.3. Market Size and Forecast By Offering
- 6.13.4. Market Size and Forecast By Application
- 6.13.5. Market Size and Forecast By End User
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. Siemens Healthineers AG (Varian)
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. Elekta AB
- 7.4.3. Accuray Incorporated
- 7.4.4. Brainlab AG
- 7.4.5. RaySearch Laboratories AB
- 7.4.6. Canon Medical Systems Corporation
- 7.4.7. Carl Zeiss Meditec AG
- 7.4.8. PTW Freiburg GmbH
- 7.4.9. BEBIG Medical GmbH
- 7.4.10. BD (Becton, Dickinson and Company)
- 7.4.11. Shanghai United Imaging Healthcare
- 7.4.12. C-RAD AB
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Europe Radiotherapy Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 6: Europe Radiotherapy Market Size and Forecast, By Offering (2020 to 2031F) (In USD Billion)
Table 7: Europe Radiotherapy Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 8: Europe Radiotherapy Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 9: Europe Radiotherapy Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 10: Germany Radiotherapy Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 11: Germany Radiotherapy Market Size and Forecast By Offering (2020 to 2031F) (In USD Billion)
Table 12: Germany Radiotherapy Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 13: Germany Radiotherapy Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 14: United Kingdom (UK) Radiotherapy Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 15: United Kingdom (UK) Radiotherapy Market Size and Forecast By Offering (2020 to 2031F) (In USD Billion)
Table 16: United Kingdom (UK) Radiotherapy Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 17: United Kingdom (UK) Radiotherapy Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 18: France Radiotherapy Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 19: France Radiotherapy Market Size and Forecast By Offering (2020 to 2031F) (In USD Billion)
Table 20: France Radiotherapy Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 21: France Radiotherapy Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 22: Italy Radiotherapy Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 23: Italy Radiotherapy Market Size and Forecast By Offering (2020 to 2031F) (In USD Billion)
Table 24: Italy Radiotherapy Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 25: Italy Radiotherapy Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 26: Spain Radiotherapy Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 27: Spain Radiotherapy Market Size and Forecast By Offering (2020 to 2031F) (In USD Billion)
Table 28: Spain Radiotherapy Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 29: Spain Radiotherapy Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 30: Russia Radiotherapy Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 31: Russia Radiotherapy Market Size and Forecast By Offering (2020 to 2031F) (In USD Billion)
Table 32: Russia Radiotherapy Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 33: Russia Radiotherapy Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 34: Competitive Dashboard of top 5 players, 2025
Figure 2: Europe Radiotherapy Market Share By Country (2025)
Figure 3: Germany Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: United Kingdom (UK) Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: France Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Italy Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: Spain Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 8: Russia Radiotherapy Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Porter's Five Forces of Global Radiotherapy Market
Radiotherapy Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (24 August, 2026)
- Notify To Team (24 August, 2026)
- Report updation (25 August, 2026)
- Report Quality Check (25 August, 2026)
- Report Dispatch (26 August, 2026)
- Hard Copy
Recently Viewed Products
Europe Radiotherapy Market Outlook, 2031
We are friendly and approachable, give us a call.